




Financial performance

Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.

Financial guidance for 2026

- QUVIVIQ sales: CHF 200 million
- Non-GAAP operating expenses: ~CHF 330 million
- Non-GAAP operating loss: ~CHF 120 million
- US GAAP operating loss: ~CHF 140 million

The financial guidance for 2026 reflects continued growth of QUVIVIQ, investment in the lucerastat registration program, and development of the company's immunology portfolio. TRYVIO/JERAYGO revenues and investments are not included, as these will be considered in any potential partnership agreement. All amounts exclude unforeseen events and any potential upsides from new direct-to-patient distribution models currently being implemented in several geographies and revenue related to additional business development activities.

Financial performance as of Sep 30, 2026

Financial
results



Liquidity and
indebtedness

Idorsia Ltd –
stock information

Financial results

Net revenue of CHF 172 million in the first nine months of 2026 resulted from product sales (CHF 142 million), product sales to partners (CHF 12 million), and contract revenues (CHF 18 million). This compares to net revenue of CHF 173 million in the first nine months of 2025 as a result of QUVIVIQ product sales (CHF 92 million), product sales to partners (CHF 3 million), and contract revenue (CHF 78 million).

US GAAP operating expenses were CHF 272 million in the first nine months of 2026, with an increase of CHF 20 million compared to the first nine months of 2025 (excluding a one-off gain of CHF 90 million in the first nine months of 2025). Cost of sales of CHF 33 million increased by CHF 21 million due to higher product sales. R&D expenses of CHF 80 million and SG&A expenses of CHF 159 million together remain almost flat.

US GAAP net loss in the first nine months of 2026 of CHF 206 million compared to CHF 34 million in the first nine months of 2025. The increased net loss was primarily driven by the increase of financial expenses of CHF 54 million (mainly non-cash interests on the debt notes, non-cash accretion of the New Money Facility loan, and non-cash debt extinguishment loss), as well as the increase in operating expenses of CHF 110 million, of which CHF 21 million related to cost of sales driven by higher product sales and CHF 90 million relate to a non-recurring one-off gain in 2025.

Financial performance as of Sep 30, 2026

> Financial results

Liquidity and indebtedness

Idorsia Ltd – stock information

Financial overview

in CHF millions, except EPS (CHF) and number of shares (millions)

	Nine Months		Third Quarter	
US GAAP results	2026	2025	2026	2025
Net revenue	172	173	62	41
Operating expenses	(272)	(162)	(98)	(87)
Operating income (loss)	(99)	23	(36)	(41)
Net income (loss)	(206)	(34)	(53)	(86)
Basic and diluted EPS	(0.80)	(0.17)	(0.20)	(0.40)
Basic and diluted weighted average number of shares	258.1	203.4	266.2	214.5

Non-GAAP* measures

Net revenue	166	167	61	37
Operating expenses	(251)	(232)	(91)	(80)
Operating income (loss)	(85)	(53)	(30)	(38)
Net income (loss)	(123)	(65)	(44)	(40)
Basic and diluted EPS	(0.48)	(0.32)	(0.17)	(0.19)
Basic and diluted weighted average number of shares	258.1	203.4	266.2	214.5

The financial statements can be found at www.idorsia.com.

** Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.*

The US GAAP net loss resulted in a net loss per share of CHF (0.80) (basic and diluted) in the first nine months of 2026, compared to a net loss per share of CHF (0.17) basic and diluted in the first nine months of 2025.

Non-GAAP measures

Non-GAAP net loss in the first nine months of 2026 amounted to CHF 123 million; the difference versus US GAAP net loss was mainly driven by depreciation and amortization (CHF 11 million), share-based compensation (CHF 9 million), accretion expenses (CHF 16 million), interest expense recognized under the R-Bridge royalty monetization agreement (CHF 6 million) and debt extinguishment loss (CHF 47 million) relating to the repayment of the New Money Facility loan, offset by non-cash revenue recognized under the R-Bridge royalty monetization agreement (CHF 7 million).

The non-GAAP net loss resulted in a net loss per share of CHF 0.48 (basic and diluted) in the first nine months of 2026, compared to a net loss per share of CHF 0.32 (basic and diluted) in the first nine months of 2025.

Liquidity and indebtedness

Liquidity on September 30, 2026, amounted to CHF 85 million. This amount does not include the remaining CHF 100 million available under the secured term loan.

(in CHF millions*)	Sept 30, 2026	June 30, 2026	Dec 31, 2025
Liquidity			
Cash and cash equivalents	85	89	89
Total liquidity	85	89	89
Indebtedness			
Convertible loan	250	250	335
Convertible bonds	44	49	49
Debt notes in the SPV**	783	766	753
Term loan	146	146	18
Other financial debt	188	186	187
Total indebtedness	1,410	1,397	1,342
Total indebtedness excl. debt notes in the SPV	627	631	589

*rounding differences may occur

** The debt notes issued by Idorsia Investments SARL ("SPV") in exchange for convertible bonds are senior secured with the shares in Idorsia Investments SARL. The A Notes only benefit from a limited and subordinated Swiss-law governed guarantee by Idorsia Ltd.

Financial performance as of Sep 30, 2026

Financial results

> Liquidity and indebtedness

Idorsia Ltd – stock information

Idorsia Ltd – shares at a glance

As of Sep 30, 2026, the company has been notified of the following shareholdings amounting to 3% or more of the company's ordinary share capital:

Major shareholders*	As of Sep 30, 2026
Jean-Paul & Martine Clozel	>20%
Rubric Capital Management	>5%
Fidelity Mt. Vernon Street Trust	>3%
FMR LLC	>3%
UBS Fund Management	>3%
Rudolf Maag	>3%

* As per the latest significant shareholder notifications available from the platform of the Disclosure Office of SIX Swiss Exchange

Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, and SSIRT.

Idorsia Ltd is traded under the following symbols:
Reuters IDIA.S / Bloomberg IDIA:SW

Key share data	as of Sep 30, 2026
Shares outstanding	269.8 million
Closing share price	CHF 4.65
Market capitalization	CHF 1.25 billion
52-week high	CHF 7.56
52-week low	CHF 2.80
YTD price change	9.19%
Average volume	1,603,030 shares
Free float	70%

Financial performance as of Sep 30, 2026

Financial results


Liquidity and indebtedness

> Idorsia Ltd – stock information

Idorsia Ltd – stock information

Share price development

(in CHF)



Stock charting tools are available at www.idorsia.com.

Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer: This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Ltd

Hegenheimermattweg 91
CH-4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com

**Financial
performance
as of Sep 30, 2026**

Latest update:
October 2026

Copyright © 2026 Idorsia Ltd

